Medrx Co Ltd

Medrx Co Ltd exhibits a highly liquid capital structure, with cash and equivalents amounting to ¥17.55 billion, representing 81.3% of total assets. The company has no long-term debt and a debt-to-equity ratio of 0.0, indicating a conservative leverage profile. The current ratio of 23.62 suggests strong short-term liquidity, well above the typical pharmaceutical industry median of 1.5-2.0. Profitability metrics are sharply negative, with a return on equity of -45.75% and a return on assets of -43.45%. These figures are well below the industry median for ROE of 10-15% and ROA of 5-8%. The company reported a net loss of ¥9.37 billion and an operating loss of ¥9.30 billion, driven by high R&D and SG&A expenses relative to revenue. The company operates in a single business segment focused on prescription drugs, with no disclosed geographic revenue breakdown. This lack of diversification increases exposure to regulatory and market risks in Japan, where the company is headquartered. No material revenue concentration by geography is reported, but the absence of international operations limits growth potential. Growth trajectory is negative, with a net loss of ¥9.37 billion in the latest period. No forward-looking revenue guidance is available, but the company's operating cash flow of -¥888.11 million and free cash flow of -¥1.01 billion indicate ongoing cash burn. The absence of capital expenditures suggests a focus on cash preservation rather than expansion. Risk factors include the high probability of continued losses and the potential for future dilution if the company requires additional capital. The risk assessment indicates low dilution risk in the near term, but the absence of long-term debt and the presence of ¥17.55 billion in cash suggest the company has sufficient liquidity to fund operations for at least 12 months. Recent events include the filing of the latest financial results, which show a significant operating and net loss. No material regulatory or litigation events were disclosed in the most recent filings. The company's reliance on a narrow product portfolio and the competitive nature of the pharmaceutical industry pose ongoing challenges.